Detalhe da pesquisa
1.
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common ß-chain cytokine receptor endocytosis.
Blood
; 139(5): 761-778, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780648
2.
Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
Eur J Haematol
; 111(6): 863-871, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37670560
3.
Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia.
Cancer
; 128(7): 1411-1417, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931301
4.
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Haematologica
; 107(11): 2641-2649, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511672
5.
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis.
Haematologica
; 105(1): 136-147, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31018977
6.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
BMC Cancer
; 18(1): 359, 2018 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29609532
7.
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Am J Hematol
; 93(11): 1301-1310, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30074259
8.
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Pediatr Blood Cancer
; 63(12): 2096-2103, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27511899
9.
Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Nature
; 466(7307): 765-8, 2010 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-20639863
10.
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Haematologica
; 104(4): e143-e146, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30409798
11.
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
JAMA Oncol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722664
12.
Intensive Reinduction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory High-Grade Myeloid Neoplasms.
Transplant Cell Ther
; 2024 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710302
13.
Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms.
J Mol Diagn
; 25(12): 932-944, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37813298
14.
Discovery of U2AF1 neoantigens in myeloid neoplasms.
J Immunother Cancer
; 11(12)2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164756
15.
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.
Clin Cancer Res
; 29(12): 2179-2183, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36547666
16.
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
JAMA Netw Open
; 6(12): e2347950, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38109114
17.
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Leuk Lymphoma
; 64(5): 927-937, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36938892
18.
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Blood Adv
; 7(17): 4950-4961, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37339483
19.
Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.
Cancers (Basel)
; 14(12)2022 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35740603
20.
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
J Natl Cancer Inst
; 114(1): 160-164, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34491344